Most / Least Popular Sectors in Japan over Last 2 Weeks....
Over the last 2 week we saw a dip in the number of Analyst Upgrade/Downgrades, most likely due to the fact Earnings is right around the corner....
629 Views
Astellas (4503) Implications of Ogeda Acquisition
At first glance, Astellas Pharma's decision to buy closely-held Belgian biotech firm Ogeda for ÂĄ90bil (US$800mil) is essentially a licensing deal...
472 Views
Xtandi (Enzalutamide) – Second Generation Androgen Receptor (AR) Signalling Inhibitor
While most of its peers struggle getting traction with new launches, Astellas is in a fortunate situation with its recently launched prostate...
453 Views
Astellas: Pfizer Buying Medivation Is the Best Possible Outcome for the Japan Pharma Firm
Pfizer is to pay US$81.50/shr for Medivation, considerably above Sanofi’s original offer of US$52.5bil. This values the Xtandi-originator at...
370 Views
Implications for Astellas as Medivation Invites Offers
Medivation appears to have finally given up hope of remaining independent and has invited tenders to be made by mid-August, with Sanofi, Pfizer,...
313 Views